^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | AFM24 (EGFR inhibitor, CD16A agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1881 - AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies
Published date:
03/10/2021
Excerpt:
AFM24’s efficacy was assessed in a xenograft mouse model using different human EGFR+ cell lines such as the TNBC cell line MDA-MB-231 and an adoptively transferred, cytokine-stimulated and expanded NK cell product. This combination of AFM24 with an NK cell product demonstrated a significant dose-dependent and differentiated reduction in tumor outgrowth as compared to mice treated with NK cell product alone.
